GAITHERSBURG, Md., March 13, 2018 (GLOBE NEWSWIRE) — OpGen, Inc. (NASDAQ:OPGN) announced today that it is collaborating with Beth Israel Deaconess Medical Center (BIDMC) in Boston on a verification study for OpGen's Acuitas® AMR Gene Panel u5.47 Assay and Acuitas Lighthouse® Knowledgebase. The principal investigator at BIDMC is Stefan Riedel, M.D., Ph.D., D(ABMM), FCAP, Associate Medical Director of the Clinical Microbiology Laboratories at BIDMC and Associate Professor of Pathology at Harvard Medical School. The study plan includes testing remnant urine specimens from patients at increased risk for complicated urinary tract infections (cUTI). This prospective verification study is among the first to evaluate potential diagnostic and antibiotic decision-making improvements that could be possible using rapid molecular testing and bioinformatics.
Effective, targeted antimicrobial treatment is of critical importance in patients with cUTI and other serious infections as the emergence and spread of antimicrobial-resistant organisms increase. There are an estimated 400,000 to 800,000 patients each year in the U.S. with cUTI, and approximately half are at risk for multidrug-resistant infections. Complicated UTI continues to be a major cause of hospital admission, morbidity, mortality and excess health care costs as a growing number of infections are healthcare-associated in origin.
The Acuitas AMR Gene Panel u5.47 is …
The post OpGen Announces Collaborator in Verification Study for Acuitas® Test appeared first on MrTopStep.com.